Structural and accessibility studies highlight the differential binding of clemizole to TRPC5 and TRPC6

Saqib, Uzma; Demaree, Isaac S.; Obukhov, Alexander G.; Baig, Mirza S.; Khan, Mohd Shahnawaz; Altwaijry, Nojood; Nasution, Mochammad Arfin Fardiansyah; Mizuguchi, Kenji; Hajela, Krishnan

doi:10.1080/07391102.2024.2306198

Journal of Biomolecular Structure and Dynamics

2024

DOI: 10.1080/07391102.2024.2306198

|View full text |Cite

Structural and accessibility studies highlight the differential binding of clemizole to TRPC5 and TRPC6

Uzma Saqib,

Isaac S. Demaree,

Alexander G. Obukhov

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Preprint1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Phytochemicals fromDaucus carotahave therapeutic potential against Triple-Negative Breast Cancer PDK1 and PLK1

Raheem,

Abayomi,

Oluwatosin

et al. 2024

Preprint

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is a deadly form of breast cancer that lacks estrogen, progesterone, and HER2 receptors. The development of drugs for TNBC has been challenging due to the lack of specific therapeutic targets. However, recent studies have shown that targeting the ATP active of the PDK-1 and PLK-1 proteins could be potential drug targets for TNBC treatment. New medications for TNBC have considerable adverse effects, highlighting the need for more targeted and effective therapies. In this study, we employed various computational approaches, including molecular docking, molecular dynamics (MD) simulations, pharmacokinetic studies, binding free energy calculations, principal component analysis (PCA), and alanine scanning analysis, to identify bioactive compounds from Daucus carota-extracted natural compounds that can bind to these ATP-binding sites and inhibit the activity of PDK1 and PLK1. Our study revealed that eight compounds showed reasonably good docking scores, binding free energies, and ADMET properties against the PDK1 and PLK1 enzymes. Astragalin and scolimoside showed substantial binding affinity and persistent interactions in the pocket region of the two proteins. Further MD simulation studies for 150 ns also suggested that the compounds were stably bound in the active site with very minor fluctuations. We believe that the identified hits for PDK1 and PLK1 from Daucus carota will be effective against TNBC in performing the biological assays.

show abstract

Phytochemicals fromDaucus carotahave therapeutic potential against Triple-Negative Breast Cancer PDK1 and PLK1

Raheem,

Abayomi,

Oluwatosin

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Structural and accessibility studies highlight the differential binding of clemizole to TRPC5 and TRPC6

Cited by 1 publication

References 39 publications

Phytochemicals fromDaucus carotahave therapeutic potential against Triple-Negative Breast Cancer PDK1 and PLK1

Phytochemicals fromDaucus carotahave therapeutic potential against Triple-Negative Breast Cancer PDK1 and PLK1

Contact Info

Product

Resources

About